论文部分内容阅读
目的研究丙型肝炎病毒（ＨＣＶ）核心（Ｃ）基因免疫用于预防和治疗ＨＣＶ感染的可行性和有效性．方法将ＨＣＶＣ基因片段插入真核表达载体ｐｃＤＮＡ３质粒ＣＭＶ启动子的下游，在证实其可以在小鼠骨髓瘤细胞ＳＰ２／０（Ｈ２ｄ）中表达之后，将重组质粒注射ＢＡＬＢ／ｃ（Ｈ２ｄ）小鼠股四头肌，ＥＬＩＳＡ检测血清中抗体产生水平；３ＨＴｄＲ掺入法测定免疫小鼠淋巴细胞ＨＣＶＣ抗原特异性增殖能力，４ｈ５１Ｃｒ释放法检测免疫小鼠细胞毒Ｔ细胞（ＣＴＬｓ）体外杀伤功能．结果免疫小鼠２０只，初次免疫２ｗｋ后，血清中均出现了ＨＣＶＣ抗体，且增加免疫剂量可提高抗体滴度；淋巴细胞增殖指数为６１０，明显高于对照组（Ｐ＜００１），ＣＴＬｓ体外特异性杀伤率为６３１％，也高于对照组（Ｐ＜００１）．结论ＨＣＶＣ基因免疫不仅可以诱导机体产生特异性的体液免疫，而且产生特异性的细胞免疫，它可能是防治ＨＣＶ的有效方法．
Objective To investigate the feasibility and effectiveness of hepatitis C virus (HCV) core (C) gene immunization for the prevention and treatment of HCV infection. Methods The HCVC gene fragment was inserted into the downstream of the CMV promoter of the eukaryotic expression vector pcDNA3. After confirming that it could be expressed in mouse myeloma cells SP2 / 0 (H2d), the recombinant plasmid was injected into BALB / c 2d) mice quadriceps muscle, ELISA detection of serum antibody levels; 3 H TdR incorporation assay lymphocyte specific immunity HCVC antigen-specific proliferation, 4h51Cr release assay immunized mouse cytotoxic T lymphocytes (CTLs) In vitro killing function. Results Twenty mice were immunized with HCVC antibodies in the first 2 weeks of immunization, and the antibody titer increased with the increase of immunization dose. The lymphocyte proliferation index was 610, which was significantly higher than that of the control group (P <001 ), CTLs specific in vitro killing rate of 63 1%, also higher than the control group (P <0 01). Conclusion HCVC gene immunization can not only induce the body to produce specific humoral immunity, but also produce specific cellular immunity, which may be an effective way to prevent and treat HCV.